`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owner.
`
`
`
`
`
`
`
`
`Case No. IPR2020-01317
`U.S. Patent No. 9,220,631
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PETITIONER’S UPDATED MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`Petitioner Regeneron Pharmaceuticals, Inc. hereby submits its updated
`
`mandatory notices pursuant to 37 C.F.R. § 42.8(a)(3).
`
`
`
`
`
`
`A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) - Unchanged
`
`The real party-in-interest is Regeneron Pharmaceuticals, Inc.
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2)) - Updated
`
`On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals
`
`Corporation, and Novartis Technology LLC filed a complaint at the U.S.
`
`International Trade Commission alleging that Petitioner infringes claims 1-6 and
`
`11-26 of U.S. Patent No. 9,220,631 (the ’631 Patent), and that a domestic industry
`
`exists with respect to claims 1-10 and 14-26 of the ’631 Patent. On the same day,
`
`Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis
`
`Technology LLC filed a complaint in the United States District Court for the
`
`Northern District of New York alleging that Petitioner infringes at least claim 1 of
`
`the ’631 Patent (N.D.N.Y. 1:20-cv-00690-TJM-CFH).
`
`On July 16, 2020, Petitioner filed the following petitions for inter partes
`
`review against the ’631 Patent: IPR2020-01317 and IPR2020-01318.
`
`
`
`On July 17, 2020, Petitioner filed a complaint in the United States District
`
`Court for the Southern District of New York against Novartis Pharma AG,
`
`Novartis Technology LLC, Novartis Pharmaceuticals Corporation (collectively
`
`“Novartis”), and Vetter Pharma International GmbH (“Vetter”) (S.D.N.Y. 1:20-cv-
`
`
`
`
`2
`
`
`
`00502-AJN). The complaint seeks judgment that (i) Novartis’s and Vetter’s
`
`conduct violates Section 1 of the Sherman Act, 15 U.S.C. § 1; (ii) Novartis’s
`
`conduct violates Section 2 of the Sherman Act, 15 U.S.C. § 2; and (iii) the ’631
`
`Patent be declared unenforceable. The complaint also seeks damages and
`
`injunctive relief restraining and enjoining Novartis and Vetter from continuing the
`
`unlawful conduct in violation of the Sherman Act.
`
`C. Lead and Back-Up Counsel and Service Information (37 C.F.R. §
`42.8(b)(3)-(4)) - Unchanged
`
`Petitioner identifies the following lead and back-up counsel and service
`
`
`
`information:
`
`Lead Counsel
`Elizabeth Stotland Weiswasser
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8022
`F: 212-310-8007
`elizabeth.weiswasser@weil.com
`USPTO Reg. No. 55,721
`
`
`Back-Up Counsel
`Anish R. Desai
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`anish.desai@weil.com
`USPTO Reg. No. 73,760
`
`Natalie Kennedy
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`natalie.kennedy@weil.com
`USPTO Reg. No. 68,511
`
`Andrew Gesior
`Weil, Gotshal & Manges LLP
`
`
`
`
`3
`
`
`
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`andrew.gesior@weil.com
`USPTO Reg. No. 76,588
`
`Brian E. Ferguson
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`brian.ferguson@weil.com
`USPTO Reg. No. 36,801
`
`Christopher M. Pepe
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`christopher.pepe@weil.com
`USPTO Reg. No. 73,851
`
`
`Please address all correspondence to lead and backup counsel. Petitioner
`
`consents to service by electronic mail at the following address:
`
`Regeneron.IPR.Service@weil.com.
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`
`
`Date: July 28, 2020
`
`
`
` Respectfully submitted,
`
`/Elizabeth Stotland Weiswasser /
`Elizabeth Stotland Weiswasser
`Reg. No. 55,721
`Lead Counsel for Petitioner
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8022
`elizabeth.weiswasser@weil.com
`
`
`
`5
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that on July 28,
`
`
`
`
`2020, a copy of PETITIONER’S UPDATED MANDATORY NOTICES
`
`PURSUANT TO 37 C.F.R. § 42.8 was sent via FedEx next business day delivery
`
`to the following:
`
`
`Michael Mazza
`Daniel Woods
`Novartis Pharmaceutical Corporation
`Intellectual Property Department
`One Health Plaza 433
`East Hanover, NJ 07936-1080
`
`
`/Timothy J. Andersen/
`Timothy J. Andersen
`Case Manager
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`202-682-7000
`timothy.andersen@weil.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`